HR of VTE for selected cancer somatic mutations
| Gene* . | HR (95% CI) . | P . | FDR q value . |
|---|---|---|---|
| STK11 | 2.12 (1.55-2.89) | .0000023 | <0.001 |
| CDKN2B | 1.45 (1.13-1.85) | .0034719 | 0.072 |
| KEAP1 | 1.84 (1.21-2.79) | .0040963 | 0.072 |
| KRAS | 1.34 (1.09-1.64) | .0058245 | 0.077 |
| SETD2 | 0.35 (0.16-0.79) | .0116198 | 0.088 |
| CTNNB1 | 1.73 (1.15-2.60) | .0089796 | 0.088 |
| MET | 1.83 (1.15-2.92) | .0111671 | 0.088 |
| CDK4 | 1.56 (1.06-2.29) | .025 | 0.148 |
| IDH1 | 0.45 (0.22-0.90) | .024 | 0.148 |
| CDKN2A | 1.26 (1.02-1.55) | .032 | 0.171 |
| SMAD4 | 1.30 (0.96-1.76) | .086 | 0.379 |
| MYC | 1.37 (0.96-1.94) | .080 | 0.379 |
| TP53 | 1.15 (0.98-1.35) | .094 | 0.382 |
| FOXA1 | 0.62 (0.33-1.16) | .133 | 0.505 |
| APC | 0.74 (0.49-1.12) | .159 | 0.561 |
| SMARCA4 | 1.34 (0.87-2.05) | .189 | 0.625 |
| Gene* . | HR (95% CI) . | P . | FDR q value . |
|---|---|---|---|
| STK11 | 2.12 (1.55-2.89) | .0000023 | <0.001 |
| CDKN2B | 1.45 (1.13-1.85) | .0034719 | 0.072 |
| KEAP1 | 1.84 (1.21-2.79) | .0040963 | 0.072 |
| KRAS | 1.34 (1.09-1.64) | .0058245 | 0.077 |
| SETD2 | 0.35 (0.16-0.79) | .0116198 | 0.088 |
| CTNNB1 | 1.73 (1.15-2.60) | .0089796 | 0.088 |
| MET | 1.83 (1.15-2.92) | .0111671 | 0.088 |
| CDK4 | 1.56 (1.06-2.29) | .025 | 0.148 |
| IDH1 | 0.45 (0.22-0.90) | .024 | 0.148 |
| CDKN2A | 1.26 (1.02-1.55) | .032 | 0.171 |
| SMAD4 | 1.30 (0.96-1.76) | .086 | 0.379 |
| MYC | 1.37 (0.96-1.94) | .080 | 0.379 |
| TP53 | 1.15 (0.98-1.35) | .094 | 0.382 |
| FOXA1 | 0.62 (0.33-1.16) | .133 | 0.505 |
| APC | 0.74 (0.49-1.12) | .159 | 0.561 |
| SMARCA4 | 1.34 (0.87-2.05) | .189 | 0.625 |
Each gene evaluated in a separate Cox proportional hazards model adjusting for chemotherapy (time-dependent covariate), a history of previous VTE, anticoagulation, presence of metastatic disease, and age at accession. The model is stratified based on tumor type and the time from a prior procedure time to accession.